Category Archives: Immunotherapy for Cancer

Alternative Cancer Treatment, Cancer Research, Cancer Treatment, Immunotherapy, Immunotherapy for Cancer, News

“Superblood” Engineered to Carry Cancer Fighting Proteins

"Superblood" Engineered to Carry Cancer Fighting Proteins
“Superblood” Engineered to Carry Cancer Fighting Proteins

Super powers are usually the stuff of comic books and movies, but a biotech startup may be turning fiction into reality with the development of “superblood” as a revolutionary new cancer treatment.

“Supercharging” Red Blood Cells

Rubius Therapeutics is working on a program called Red-Cell Therapeutics (RCT), which involves red blood cells that are genetically engineered to fight cancer. Once introduced into a patient’s system, these proteins can replace missing enzymes and help the immune system attack and destroy cancer cells.

RCT has two major advantages that make it a promising breakthrough in cancer treatment:

– The nuclei have been removed from these cells so they can’t be recognized by the immune system, leaving them free from interference so they can do their job.

– Red blood cells travel throughout the entire body, so RCT is able to easily reach any affected organs or tissues.

Thanks to these two features, RCT has the potential to treat patients without the need for an individually developed solution.

What’s Next?

Initially, Rubius Therapeutics generated $120 million from investors. The company recently raised an additional $100 million for a total of nearly a quarter of a billion dollars in less than one year. According to Rubius president Torben Straight Nissen, this funding will help accelerate RCT development for quicker delivery to the end users.

Issels®: The Leader in Immunotherapy Cancer Treatments

Much like RCT, cancer treatment at Issels® is designed to boost the immune system’s ability to attack and kill cancer cells. Contact us to learn more about cancer vaccines and other programs we have used to help patients achieve long-term remission.

After Cancer, Cancer Survivors, Immunotherapy, Immunotherapy for Cancer, News

An Immunotherapy and Ovarian Cancer Success Story

1 Comment
An Immunotherapy and Ovarian Cancer Success Story
An Immunotherapy and Ovarian Cancer Success Story

What happens when a patient responds to cancer immunotherapy that, according to advanced medical knowledge, shouldn’t work? Scientists are studying four recent cases where cancer treatment “broke the rules.”

Exceptions to the Rule?

Four women in different countries, who knew each other only through an online support group, were diagnosed with the same rare form of ovarian cancer. Each one persuaded her doctor to use immunotherapy drugs, despite conventional wisdom that the treatment was useless against ovarian cancer.

Against all odds, the patients responded positively, with their tumors going into remission and the women returning to their normal lives. Researchers are hoping to gain insight that will help develop cancer immunotherapy treatments with a broader range of applications.

Why Doctors Were Caught by Surprise

Tumor cells have an ability to deflect attacks from the body’s immune system, allowing them to multiply freely. Immunotherapy is a way of helping the immune system identify and kill cancer cells.

So far immunotherapy has been successful primarily with lung cancer, melanoma and forms with many genetic mutations. By contrast, hypercalcemic ovarian cancer, which is the form that affected the four women, is driven by a single mutation.

The theory is that a lower number of mutations “tricks” the immune system into disregarding the threat posed by cancer cells. Based on the positive results in the women with ovarian cancer, scientists at Johns Hopkins and M.D. Anderson Cancer Center are conducting trials with the aim of further refining cancer immunotherapy.

Comprehensive Cancer Immunotherapy Treatments at Issels®

Our individually created immunotherapy programs are often successful where other conventional treatments have failed. Contact us for more information.

Alternative Cancer Treatment, Cancer Research, Immunotherapy for Cancer, News, Uncategorized

New Swedish Study Shows Selenium-containing Enzyme May Combat Cancer

New Swedish Study Shows Selenium-containing Enzyme May Combat Cancer
New Swedish Study Shows Selenium-containing Enzyme May Combat Cancer

One of the challenges of cancer treatment research is distinguishing between effects on healthy cells and tumor cells. Scientists in Sweden have been focusing on inhibiting a chemical that is beneficial to human health but also promotes the growth of cancer.

The Connection Between Selenium Intake and Cancer

Selenium is a chemical element with a Recommended Dietary Allowance determined by the Food and Drug Administration. An enzyme known as TrxR1 contains selenium, which supports cell growth and protects them from oxidative stress. Raised levels of TrxR1 are also associated with occurrences of cancer, although the causes are not yet understood.

While TrxR1 inhibitors are available, a research team at Karolinska Institutet in Sweden analyzed nearly 400,000 molecules looking for new and more specific versions. Their search turned up three molecules, which the scientists used to treat more than 60 types of cancer cells under laboratory conditions.

Treating Cancer While Sparing Healthy Cells

Healthy cells proved to be far less vulnerable to the TrxR1 inhibitors. Team leader Professor Elias Arner explained that the difference may be caused by cancer cells having a greater vulnerability to oxidative stress than normal cells.

Cisplatin, melfalan and some of the other cancer drugs currently in use contain TrxR1 inhibitors, although not the ones that were the focus of this study. It’s unclear whether the TrxR1 inhibition factor plays a role in the effectiveness of the drugs, but researchers will continue investigating these new molecules as cancer treatments.

Cancer Treatment Designed for Your Needs

Issels® has a successful history of creating individual cancer treatment programs addressing a patient’s particular needs. Contact us for more information.

Alternative Cancer Treatment, Cancer Research, Cancer Treatment, Immunotherapy, Immunotherapy for Cancer, Uncategorized

Immunotherapy is Changing Cancer Treatment Again in Exciting New Ways

2 Comments
Immunotherapy is Changing Cancer Treatment Again in Exciting New Ways
Immunotherapy is Changing Cancer Treatment Again in Exciting New Ways

If you think you’ve been hearing the term “immunotherapy” a lot lately, it’s not your imagination. Scientists consider this growing form of cancer treatment to be a game-changer on a par with the polio vaccine and organ transplants.

Researchers Commit to Immunotherapy

The University of Pittsburgh Medical Center, one of the top-rated health enterprises in the U.S., recently demonstrated their major commitment to immunotherapy research. Earlier this year, they announced plans for a $200 million Immune and Transplant Therapy facility to open in 2020.

UPMC’s newest center will focus on researching treatments to disrupt cancer growth as well as reduce the need for immune-suppressing drugs with transplant patients. Dr. Robert Ferris, director of UPMC’s Hillman Cancer Center, referred to the facility as “swinging for the fences.”

How Immunotherapy Works

Immunotherapy cancer treatments fall into one of two categories:

– Checkpoint modulator drugs trigger the body’s own immune cells to attack and destroy cancer cells.

– Cell therapies, such as the recently approved CAR-T therapy, involve harvesting a patient’s T-cells and programming them to fight cancer cells, at which point they are reinfused back into the patient’s system.

Dr. Sandip Patel of the University of California San Diego called immunotherapy a “paradigm shift” in cancer treatment. According to Patel, when immunotherapy is effective, it can lead to a patient’s cancer going into remission for years.

Issels®: A Pioneer in Immunotherapy Cancer Treatments

Our founder, Dr. Josef M. Issels, predicted the rise of immunotherapy more than 20 years ago. Visit our website to learn more about Issels® and our innovative approach to non-toxic, individually created cancer treatment programs.

Cancer Research, Cancer Treatment, Cancer Vaccine, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, News, Uncategorized

Huntington’s Disease Produced Molecules Are Fatal to Cancer Cells

Huntington's Disease Produced Molecules Are Fatal to Cancer Cells
Huntington’s Disease Produced Molecules Are Fatal to Cancer Cells

Could a clue to more effective cancer treatment be found in the biochemistry of another illness? Scientists are hopeful that the gene behind Huntington’s disease could be fatal to cancer cells without harming healthy ones.

What Is Huntington’s Disease?

Huntington’s disease is a genetically inherited condition that destroys nerve cells in the brain. There is currently treatment but no cure for the disorder, which causes a slowly progressive decline in both cognitive and physical abilities.

The faulty gene that triggers Huntington’s disease contains an excessive number of repeats of a certain sequence of nucleotides, which form the building blocks of DNA and RNA. These sequences create small interfering RNAs, which are molecules that attack specific genes crucial for cell survival.

“Assassin Molecules”

Brain cells in particular are vulnerable to the cell death caused by small interfering RNAs. Cancer cells are also highly susceptible, which is thought to be the reason why Huntington’s disease patients have such a low incidence of cancer.

A research team at Northwestern University tested these so-called “assassin molecules” on human and mouse cancer cells, including brain, breast, colon and ovarian, that were grown in a laboratory. The small interfering RNAs killed all cancer cells from both humans and mice.

Researchers were encouraged that the treatment also showed no toxicity to healthy cells. Further testing is underway to find a more targeted form of delivery.

Targeted Cancer Treatment at Issels®

Our individually developed, non-toxic immunotherapy programs focus on destroying cancer cells and their environment while sparing healthy tissues. Contact us for more information about cancer vaccines and other targeted cancer treatment protocols at Issels®.

Alternative Cancer Treatment, Cancer Research, Cancer Treatment, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, Uncategorized

Ribosomes May be Hijacked to Protein Fuel for Cancers

It's Time to Stop Cancer
It’s Time to Stop Cancer

Cancer cells often have an uncanny ability to hijack the functions of normal body cells. Scientists have focused on this property in the belief that deciphering the process will lead to more effective cancer treatment.

Thanks to the results of a Yale University study, the scientific community may be a little closer to this goal. Discovery of unknown pathways to fuel sources provides insights into the development and growth of cancer.

How Cell Proteins Drive Cancer Growth

Organelles are specialized structures in cells that carry out certain tasks, much like organs do for the human body. One of these organelles, called the nucleolus, produces ribosomes, which in turn manufacture proteins.

Ribosomes can be hijacked by cancer cells to divert protein production in order to fuel cancer growth. In a study published in Cell Reports, Dr. Susan Baserga of Yale University and two of her graduate students screened 18,000 proteins that are vital to nucleoli formation.

A Target for Immunotherapy Cancer Treatment?

Dr. Baserga and her team found 139 proteins that serve as a type of master switching network. The proteins represent countless cellular pathways that control the production of ribosomes. This discovery clarifies the link between ribosomes and cancer as well as the one between ribosomes and certain birth defects known as ribosomopathies.

Personalized Cancer Treatment at Issels®

Our innovative cancer treatments target both the tumor and its microenvironment. Immunotherapy programs at Issels® are created specifically to address a patient’s individual needs.

Contact us to learn how our effective cancer treatments have helped patients whose advanced cancers were non-responsive to traditional therapies.